

Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Cardiovascular and Renal Drugs Advisory Committee
March 18, 2009
Marriott Conference Centers,
UMUC Inn and Conference Center by Marriott,
3501 University Blvd., East, Adelphi, MD.

Proposed Meeting Roster

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS

VOTING

Robert A. Harrington, M.D., F.A.C.C. (Chair)
Professor of Medicine, Division of Cardiology,
Department of Medicine,
Duke University Medical School
Duke Clinical Research Institute
2400 Pratt Street, NP 7007
Room 0311, Terrace Level
Durham, North Carolina 27705

A. Michael Lincoff, MD, FACC
Vice Chairman for Clinical Research,
Lerner Research Institute Vice Chairman,
Department of Cardiovascular Medicine
Professor of Medicine
Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, Ohio 44195

Henry R. Black, M.D.
Clinical Professor of Internal Medicine,
Department of Internal Medicine
New York University School of Medicine
550 First Avenue
New York, New York 10016

Darren K. McGuire, M.D., M.H.Sc., F.A.C.C.
Associate Professor of Medicine
University of Texas Southwestern
Medical Center
5323 Harry Hines Boulevard
St. Paul Hospital, Suite HA9.133
Dallas, Texas 75390

Sanjay Kaul, M.D.
Director, Cardiovascular Diseases Fellowship
Training Program, Cedars-Sinai Heart Institute
Division of Cardiology, Room 5536 S. Tower
8700 Beverly Blvd
Los Angeles, California 90048

James D. Neaton, Ph.D.
Professor of Biostatistics
Division of Biostatistics
Coordinating Centers for Biometric Research
University of Minnesota School of Public Health
2221 University Avenue S.E., Suite 200
Minneapolis, Minnesota 55414

Mori J. Krantz, M.D., F.A.C.C.
Associate Professor, University of
Colorado/Cardiology, Denver Health
Director, CV Prevention, & ECG Core Lab
Colorado Prevention Center
789 Sherman St. Suite 200
Denver, Colorado 80203

Emil P. Paganini, M.D., F.A.C.P., F.R.C.P.
Critical Care Nephrology Consulting
10427 Mayfield Road
Chesterland, Ohio 44026

NON-VOTING

Jonathan C. Fox, MD, Ph.D., F.A.C.C.
(Industry Representative)
Vice President, Clinical Therapeutic Area
Cardiovascular and Gastrointestinal Diseases
AstraZeneca LP
PO Box 15437
Wilmington, Delaware 19850-5437

Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Cardiovascular and Renal Drugs Advisory Committee
March 18, 2009
Marriott Conference Centers,
UMUC Inn and Conference Center by Marriott,
3501 University Blvd., East, Adelphi, MD.

TEMPORARY VOTING MEMBERS

William Calhoun, M.D.

Sealy and Smith Distinguished Professor
Vice Chair for Research
Department of Internal Medicine
University of Texas Medical Branch
4118 John Sealy Annex- Route 0568
301 University Boulevard
Galveston, Texas 77555

Erik R. Swenson, M.D.

Professor of Medicine,
and of Physiology and Biophysics
Pulmonary and Critical Care Medicine
Veterans Affairs Puget Sound
Health Care System
1660 South Columbian Way
Seattle, Washington 98108

Robert M. Dubbs

(Patient Representative)
West Palm Beach, Florida 33412

Sidney M. Wolfe, M.D.

(Acting Consumer Representative)
Director, Health Research Group of
Public Citizen
1600 20th St. NW
Washington, DC. 20009

Lewis Nelson, M.D.

Director
Fellowship in Medical Toxicology
New York University School of Medicine
455 First Avenue, Room 123
New York, New York 10016

FDA (NON-VOTING)

Robert Temple, M.D.

Director of the Office of Medical Policy
Director, Office of Drug Evaluation I
CDER

Norman Stockbridge, M.D.

Director, Division of Cardiovascular and
Renal Drug Products
CDER